Can a Precision-Engineered transplant rebuild immunity in babies born without it?
NCT ID NCT03597594
First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time
Summary
Infants with severe combined immunodeficiency (SCID) lack working immune cells and face life-threatening infections. A matched sibling donor transplant is the standard cure, but most babies do not have one. This trial tests a refined transplant using a parent or other partially matched donor, with specific immune cells removed from the graft to reduce the risk of severe graft-versus-host disease. Researchers also give a second infusion of selected donor cells to speed immune recovery. The goal is to see whether this approach is safe and helps these infants survive with a working immune system.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- A refined donor-cell transplant using TCRα/β-depleted and CD45RA-depleted cells
- What this could lead to
- If it works, this approach could give infants with SCID a safer transplant option when no matched sibling donor exists, rebuilding immunity without severe graft-versus-host disease.
- What could go wrong
- This is a small, early-phase trial in a fragile infant population. The transplant may fail to engraft, infections may still occur, or graft-versus-host disease may develop despite the cell-depletion strategy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
4 people
The number who actually took part.
- Started
-
Sep 2021
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
2 months and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria - Transplant Recipient * Age ≥2 months old at the time of chemotherapy administration * A proven mutation as defined by direct sequencing of patient DNA * Has a suitable matched sibling donor or matched unrelated donor (8/8) or single haplotype matched (≥3 of 6) family member donor * Patient must fulfill pre-transplant evaluation: * Left ventricular ejection fraction \>40% and no evidence of uncorrected congenital malformation with clinical symptomatology * Creatinine clearance (CrCl) or glomerular filtration rate (GFR) ≥ 50 ml/min/1.73m2 or serum Creatinine ≤1.2mg/dL * Resting pulse oximetry ≥90% on room or ≥95% on oxygen supplementation * Lansky (age-dependent) performance score ≥50 * Bilirubin ≤3 times the upper limit of normal for age * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5 times the upper limit of normal for age Exclusion Criteria - Transplant Recipient * Positive for HIV infection by genome PCR * Presence of active malignancy * A social situation indicating that the family may not be able to comply with protocol procedures and recommended medical care * Presence of a medical condition indicating that survival will be dismal such as the requirement for mechanical ventilation, severe failure of a major organ system, or evidence of a serious, progressive infection that is refractory to medical therapy Inclusion Criteria - Matched Sibling Donor and Haplocompatible Donor * Fully matched sibling donor (8/8), or matched unrelated donor (8/8), or at least single haplotype matched (≥3 of 6) family member * At least 1 year old (MSD) and at least 18 years of age (Haplocompatible) * HIV negative * Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment (if female) * Not breast feeding * Regarding donation eligibility, is identified as either: * Completed the process of donor eligibility determination as outlined in 21 CFR 1271 and agency guidance; OR * Does not meet 21 CFR 1271 eligibility requirements, but has a declaration of urgent medical need completed by the principal investigator or physician sub-investigator per 21 CFR 1271
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Severe combined immunodeficiency are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gene therapy offers hope for 'Bubble Boy' disease, but leukemia risk remains
- Milder stem cell transplant shows promise for kids with immune disorders
- New stem cell filter could make transplants safer for vulnerable patients
- Gene therapy offers new hope for babies with rare 'Bubble Boy' disease
- New stem cell approach could fix immune systems in kids
- Scientists hunt for genetic clues behind rare immune disorder